Oro-Medonte receives Barrie's ‘high-level' proposal, counters with terms
Last week, Springwater Township council
rejected receiving Barrie Mayor Alex Nuttall's presentation
, 'Proposed Principles for Boundary Adjustment Agreement, City of Barrie and Township of Springwater,' by a vote of 5-2.
During its meeting on Wednesday, Oro-Medonte Township council voted unanimously to accept a
similar proposal letter
from Nuttall, dated May 13, and respond to it with their own set of guiding principles.
'The communication from the City of Barrie does speak for itself in terms of what is before council today,' said Shawn Binns, chief administrative officer for Oro-Medonte.
'This comes from a meeting that was held with the mayor and the deputy (mayor) and myself to understand the facts of the proposal that was put forward by the City of Barrie. I think there's a lot of misconceptions in terms of an agreement and tabling an agreement for council's consideration.'
According to Binns, the letter the township received was 'a high-level proposal' with general terms and principles that have been outlined by Barrie for Oro-Medonte council's consideration.
'In no way, shape or form, at this point, is council looking to accept it,' Binns stressed. 'We're still going through the process and we have the ability, I think, to influence that process.'
The township drafted a motion that would receive Nuttall's proposal and would articulate the principles that would go back to the City of Barrie and the provincial land development facilitation process to guide future discussions.
'They've come forward to us with a set of terms and principles on behalf of Barrie,' Oro-Medonte Mayor Randy Greenlaw said.
'What we need to do is reply, outlining the terms and principles which we think are an acceptable path forward, which will be merged into the facilitation process moving forward.'
Those principles are:
Coun. David Clark supported the decision to keep the conversation going.
'What this motion is doing is establishing our continued belief in how this process should go,' he said. 'The City of Barrie has made an offer and we say, 'Thank you for the offer, we're not interested,' but we want to continue to have these discussions with the most pertinent and important information at hand.
'I think it's important to stay engaged,' Clark added.
Talk of annexation started about 18 months ago, when, on Nov. 6, 2023, Nuttall presented to the standing committee on heritage, infrastructure and cultural policy
during a meeting in Barrie
.
At that time, he provided the committee with an update on Barrie's housing targets and highlighted why the city requires additional employment land so more residents can have jobs closer to home.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
01-07-2025
- Yahoo
Bill to improve transit for Mecklenburg County advances through the General Assembly
MECKLENBURG COUNTY, N.C. (QUEEN CITY NEWS) — Plans to expand and improve Mecklenburg County's transportation infrastructure are one step closer to becoming reality. State senators voted Wednesday afternoon to pass HB 948, legislation that would allow voters to approve a new, one-cent sales tax in the county to fund transit initiatives. 'We're thrilled that the General Assembly has shown their support both in the House and the Senate for this bill. I think it goes to show that they understand that being able to continue to move efficiently is very important for any municipality in the state,' said Shannon Binns with Sustain Charlotte, a local nonprofit backing the tax. PREVIOUS | HB 948, also known as the P.A.V.E. Act, would enable the county to gather revenue to pay for a light rail expansion, improvements to roads throughout the county, and create new, faster bus routes. Legislators said 40 percent of revenue would go directly to municipalities, and 60 percent would go to a new, yet to be established, transit authority. 'This is what people in our area said they wanted, so we just are grateful they realized this is a local need,' said Binns. The one-cent tax and related plan have a lot of support throughout the county, including from Charlotte and the Town of Davidson. But leaders in Matthews oppose the tax, frustrated that the town was not included in a planned light rail expansion, set to be named the Silver Line. At Wednesday night's Metropolitan Transit Commission meeting, Charlotte Mayor Vi Lyles expressed her appreciation of the bill's authors, most of whom are from Mecklenburg County. 'We're very grateful to the relationships we've built, and the relationships that made this possible,' she said. 'I truly believe it is something that changes the way the city grows and the towns and the county doing something that we haven't had the funding to accomplish. We're really looking forward to the improvements to be made for all of our citizens.' Supporters hope to have the tax before voters during the municipal elections set for November 2025. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
02-06-2025
- Yahoo
Lightcast Appoints Industry Veteran Philip Binns as Chairman of the Board
Former Agilent executive to help guide commercial growth strategies for groundbreaking benchtop single-cell functional analysis platform CAMBRIDGE, England & CAMBRIDGE, Mass., June 02, 2025--(BUSINESS WIRE)--Lightcast, a pioneering life science tools company, today announced the appointment of Philip Binns as chairman of its board of directors, effective May 1, 2025. With this appointment, the Lightcast board includes one investor director each from Arch Ventures, Illumina Ventures, M-Ventures, and Longwall Ventures; two independent directors, Kevin Knopp, CEO of 908 Devices, and Kevin Hrusovsky, chairman and former CEO of Quanterix; and observers from OMX Ventures, +ND Capital, and Terra Magnum. "We are thrilled to add Phil to our highly experienced board," said Paul Loeffen, PhD, CEO of Lightcast. "His extensive industry expertise and proven leadership will be invaluable as we evolve from a product development-focused company into a fully commercial organization, expanding our global reach and maximizing our impact in the life sciences market." Mr. Binns brings decades of experience in scientific instrumentation and leadership, recently serving as president of the life sciences and applied markets group at Agilent Technologies. He joined Agilent in 2010 through its acquisition of Varian, Inc., where he played a pivotal role in expanding the company's atomic and molecular spectroscopy portfolio into a market-leading business. In addition to his new role at Lightcast, Mr. Binns serves as chair and non-executive director of Epiminder, a company developing implantable brain-monitoring devices; as a director of the Bionics Institute, a globally recognized medical device research organization; and as a National Council Advisor to the Australian Industry AI Group. He holds a degree in business management from the University of Melbourne and an MBA from Melbourne Business School. "The Lightcast Envisia™ platform has the potential to transform single-cell analysis by unlocking functional insights that were previously out of reach," said Binns. "The company is at an exciting inflection point, and I'm eager to collaborate with this talented team to support the platform's global adoption and help drive the next generation of biologics and therapies." While traditional single-cell analysis techniques often rely on genomic data to infer function, the benchtop Envisia platform uses droplet microfluidics to perform highly controlled, sequential single-cell functional assays that capture rich functional data sets to improve decision making. Built around Lightcast's proprietary light-controlled droplet manipulation technology, the platform enables parallel interrogation of tens of thousands of picoliter-scale droplets, offering unmatched precision and flexibility. By integrating functional screening early in the antibody discovery process, the Envisia platform allows researchers to select and advance the most promising candidates. It also opens new possibilities in cell-cell interaction studies and broader applications in immunology and oncology. Lightcast recently announced the limited commercial release of its Envisia benchtop platform. The company is actively collaborating with leading pharmaceutical and academic institutions to validate performance, optimize protocols, and expand application areas. These efforts will support the full commercial launch of a comprehensive suite of validated protocols later in 2025. The complete Envisia workflow will include advanced instrumentation, intelligent software, a purpose-built cartridge system, and assay kits optimized for a broad range of cell types, assay formats, and research applications. To learn more about the Envisia platform, visit About Lightcast Lightcast aims to unleash new capabilities within the single-cell analysis field by developing a more accessible, scalable, and flexible platform for scientists in basic, translational, and applied research. These capabilities will empower new biological discoveries and accelerate the development of novel drugs, therapies, and biologics. Founded in 2019 and based in Cambridge, UK, Lightcast has invented a technology that uses rays of light to control picoliter-scale droplets for functional analysis of individual cells. For more information, visit Lightcast, the Lightcast logo, and Envisia are trademarks of Lightcast Discovery Ltd. View source version on Contacts For further information Andrew Noble for Lightcastandrew@ +1 (415) 722-2129 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
02-06-2025
- Business Wire
Lightcast Appoints Industry Veteran Philip Binns as Chairman of the Board
CAMBRIDGE, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Lightcast, a pioneering life science tools company, today announced the appointment of Philip Binns as chairman of its board of directors, effective May 1, 2025. With this appointment, the Lightcast board includes one investor director each from Arch Ventures, Illumina Ventures, M-Ventures, and Longwall Ventures; two independent directors, Kevin Knopp, CEO of 908 Devices, and Kevin Hrusovsky, chairman and former CEO of Quanterix; and observers from OMX Ventures, +ND Capital, and Terra Magnum. "We are thrilled to add Phil to our highly experienced board," said Paul Loeffen, PhD, CEO of Lightcast. "His extensive industry expertise and proven leadership will be invaluable as we evolve from a product development-focused company into a fully commercial organization, expanding our global reach and maximizing our impact in the life sciences market." Mr. Binns brings decades of experience in scientific instrumentation and leadership, recently serving as president of the life sciences and applied markets group at Agilent Technologies. He joined Agilent in 2010 through its acquisition of Varian, Inc., where he played a pivotal role in expanding the company's atomic and molecular spectroscopy portfolio into a market-leading business. In addition to his new role at Lightcast, Mr. Binns serves as chair and non-executive director of Epiminder, a company developing implantable brain-monitoring devices; as a director of the Bionics Institute, a globally recognized medical device research organization; and as a National Council Advisor to the Australian Industry AI Group. He holds a degree in business management from the University of Melbourne and an MBA from Melbourne Business School. "The Lightcast Envisia™ platform has the potential to transform single-cell analysis by unlocking functional insights that were previously out of reach," said Binns. "The company is at an exciting inflection point, and I'm eager to collaborate with this talented team to support the platform's global adoption and help drive the next generation of biologics and therapies." While traditional single-cell analysis techniques often rely on genomic data to infer function, the benchtop Envisia platform uses droplet microfluidics to perform highly controlled, sequential single-cell functional assays that capture rich functional data sets to improve decision making. Built around Lightcast's proprietary light-controlled droplet manipulation technology, the platform enables parallel interrogation of tens of thousands of picoliter-scale droplets, offering unmatched precision and flexibility. By integrating functional screening early in the antibody discovery process, the Envisia platform allows researchers to select and advance the most promising candidates. It also opens new possibilities in cell-cell interaction studies and broader applications in immunology and oncology. Lightcast recently announced the limited commercial release of its Envisia benchtop platform. The company is actively collaborating with leading pharmaceutical and academic institutions to validate performance, optimize protocols, and expand application areas. These efforts will support the full commercial launch of a comprehensive suite of validated protocols later in 2025. The complete Envisia workflow will include advanced instrumentation, intelligent software, a purpose-built cartridge system, and assay kits optimized for a broad range of cell types, assay formats, and research applications. To learn more about the Envisia platform, visit About Lightcast Lightcast aims to unleash new capabilities within the single-cell analysis field by developing a more accessible, scalable, and flexible platform for scientists in basic, translational, and applied research. These capabilities will empower new biological discoveries and accelerate the development of novel drugs, therapies, and biologics. Founded in 2019 and based in Cambridge, UK, Lightcast has invented a technology that uses rays of light to control picoliter-scale droplets for functional analysis of individual cells. For more information, visit Lightcast, the Lightcast logo, and Envisia are trademarks of Lightcast Discovery Ltd.
